Extreme Movers: Grok 4.5's picks for 2026-09-09
Grok 4.5 picked INTC, AMGN, ROIV, FCEL, SEI for a 1-day horizon. Average directional return: +0.41%. Directions called correctly: 80%.
| Experiment | Extreme Movers |
|---|---|
| Model | Grok 4.5 |
| Prompt version | extreme-movers-v6 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-09-08 |
| Measured to | 2026-09-09 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | +0.41% |
| Directions called correctly | 80% |
| Benchmark return | -0.46% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | INTC | up | +1.69% | +1.69% | 65% | +2.16% | Yes |
| 2 | AMGN | down | -0.48% | +0.48% | 62% | +0.95% | Yes |
| 3 | ROIV | up | +0.80% | +0.80% | 58% | +1.26% | Yes |
| 4 | FCEL | up | -6.70% | -6.70% | 55% | -6.24% | No |
| 5 | SEI | up | +5.80% | +5.80% | 52% | +6.27% | Yes |
The model's market view
September 8 session featured strong semiconductor and energy moves alongside sharp healthcare declines tied to clinical and sector news. Extreme movers with verifiable prices and market caps above the exclusion threshold offer continuation or reversal opportunities into the next session.
Why each pick
INTC
Intel closed up 9.05% at $104.47 on reports of potential CPU price increases and analyst upgrades amid the broader semiconductor rally. The move is substantive, driven by company-specific catalysts and AI/foundry momentum. Hypothesis of continuation reflects residual buying interest. Risks include profit-taking after the large one-day gain.
AMGN
Amgen fell 10.08% to $393.17 after concerns linked to a competitor’s failed Phase 3 cardiovascular trial raised questions for its own pipeline. The catalyst is substantive (clinical read-across). Hypothesis of continuation expects further pressure from healthcare sector weakness. Risks include a bounce if the market deems the impact overstated.
ROIV
Roivant Sciences rose approximately 18.75% to around $41.48 on elevated volume. The move appears tied to biotech sector rotation and company-specific developments. Hypothesis of continuation reflects momentum in higher-beta healthcare names that outperformed. Risks are the speculative nature of biotech swings and potential mean-reversion.
FCEL
FuelCell Energy gained 18.80% to $17.76. The advance is largely speculative, linked to broader alternative-energy and infrastructure themes rather than a discrete company catalyst. Hypothesis of continuation captures short-term momentum. Risks include high volatility and rapid reversal typical of speculative energy names.
SEI
Solaris Energy Infrastructure advanced roughly 16% to about $63.96 amid energy sector strength tied to higher oil prices. The catalyst is substantive (geopolitical oil premium supporting energy infrastructure). Hypothesis of continuation aligns with ongoing Middle East supply concerns. Risks include oil-price volatility and sector rotation away from energy.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| GPT-5.6 Sol | ROIV, BSX, LITE, BE, AMGN | +0.43% | 60% |
| Muse Spark 1.1 | CBRS, SNDK, IONQ, GME, CEG | -2.61% | 20% |
| Gemini 1.5 Pro | ROIV, SMR, SEI, DYN, FCEL | -1.90% | 40% |
| Gemini 3 Pro | ROIV, SMR, CRWV, INTC, GPRO | -0.59% | 60% |
| Claude Opus 5 | FCX, AMD, SRPT, QCOM, SYK | -0.34% | 40% |
Written up on ForecastNest Insights: Extreme Movers: Grok 4.5's picks for 2026-09-09.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.